Switch theme
Sign up to access all valuation multiples
Australian Clinical Labs is Australia’s third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
2016
4.9K+
LTM Revenue $478M
LTM EBITDA $131M
$548M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Australian Clinical Labs has a last 12-month revenue (LTM) of $478M and a last 12-month EBITDA of $131M.
In the most recent fiscal year, Australian Clinical Labs achieved revenue of $443M and an EBITDA of $109M.
Australian Clinical Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Australian Clinical Labs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $478M | XXX | $443M | XXX | XXX | XXX |
| Gross Profit | $395M | XXX | $366M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $131M | XXX | $109M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $43.9M | XXX | $35.9M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $22.6M | XXX | $15.4M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $18.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Australian Clinical Labs's stock price is AUD 3 (or $2).
Australian Clinical Labs has current market cap of AUD 560M (or $360M), and EV of AUD 853M (or $548M).
See Australian Clinical Labs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $548M | $360M | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Australian Clinical Labs has market cap of $360M and EV of $548M.
Australian Clinical Labs's trades at 1.2x EV/Revenue multiple, and 4.6x EV/EBITDA.
Equity research analysts estimate Australian Clinical Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Australian Clinical Labs has a P/E ratio of 15.9x.
See valuation multiples for Australian Clinical Labs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $360M | XXX | $360M | XXX | XXX | XXX |
| EV (current) | $548M | XXX | $548M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 4.2x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBIT | 12.5x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.9x | XXX | 18.8x | XXX | XXX | XXX |
| EV/FCF | 8.5x | XXX | 6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAustralian Clinical Labs's last 12 month revenue growth is 5%
Australian Clinical Labs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Australian Clinical Labs's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Australian Clinical Labs's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Australian Clinical Labs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Australian Clinical Labs acquired XXX companies to date.
Last acquisition by Australian Clinical Labs was XXXXXXXX, XXXXX XXXXX XXXXXX . Australian Clinical Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Australian Clinical Labs founded? | Australian Clinical Labs was founded in 2016. |
| Where is Australian Clinical Labs headquartered? | Australian Clinical Labs is headquartered in Australia. |
| How many employees does Australian Clinical Labs have? | As of today, Australian Clinical Labs has 4.9K+ employees. |
| Who is the CEO of Australian Clinical Labs? | Australian Clinical Labs's CEO is Ms. Melinda McGrath. |
| Is Australian Clinical Labs publicy listed? | Yes, Australian Clinical Labs is a public company listed on ASX. |
| What is the stock symbol of Australian Clinical Labs? | Australian Clinical Labs trades under ACL ticker. |
| When did Australian Clinical Labs go public? | Australian Clinical Labs went public in 2021. |
| Who are competitors of Australian Clinical Labs? | Similar companies to Australian Clinical Labs include e.g. Healius, Integral Diagnostics, Sonic Healthcare, Bangkok Dusit Medical Services. |
| What is the current market cap of Australian Clinical Labs? | Australian Clinical Labs's current market cap is $360M |
| What is the current revenue of Australian Clinical Labs? | Australian Clinical Labs's last 12 months revenue is $478M. |
| What is the current revenue growth of Australian Clinical Labs? | Australian Clinical Labs revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Australian Clinical Labs? | Current revenue multiple of Australian Clinical Labs is 1.1x. |
| Is Australian Clinical Labs profitable? | Yes, Australian Clinical Labs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Australian Clinical Labs? | Australian Clinical Labs's last 12 months EBITDA is $131M. |
| What is Australian Clinical Labs's EBITDA margin? | Australian Clinical Labs's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Australian Clinical Labs? | Current EBITDA multiple of Australian Clinical Labs is 4.2x. |
| What is the current FCF of Australian Clinical Labs? | Australian Clinical Labs's last 12 months FCF is $64.3M. |
| What is Australian Clinical Labs's FCF margin? | Australian Clinical Labs's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Australian Clinical Labs? | Current FCF multiple of Australian Clinical Labs is 8.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
